Clinical Data

The approval of Mydayis was supported by three large, randomized, placebo-controlled, phase III studies in adults and one randomized, placebo-controlled, phase III study in pediatric patients (aged 13-17). The onset and duration of effect was demonstrated in two phase II studies in adults and one phase II study in adolescents 13-17 years of age.1

COMMITTED TO ADHD

For over 20 years, Shire has been committed to ADHD research to help meet the needs of patients.

Reference
  1. Mydayis [package insert]. Lexington, MA; Shire US Inc.